Publications by authors named "Perttu Koskenvesa"

18Publications

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

Leuk Res 2020 03 23;90:106310. Epub 2020 Jan 23.

Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Section of Hematology, Uppsala University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106310DOI Listing
March 2020

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.

Leukemia 2018 07 20;32(7):1643-1656. Epub 2018 Jun 20.

Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0175-0DOI Listing
July 2018

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

J Cancer Res Clin Oncol 2017 Aug 23;143(8):1543-1554. Epub 2017 Mar 23.

Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-017-2378-6DOI Listing
August 2017

Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.

J Adv Nurs 2016 Sep 26;72(9):2196-206. Epub 2016 Apr 26.

Division of Pharmacology and Pharmacotherapy, University of Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jan.12978DOI Listing
September 2016

Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.

Patient Prefer Adherence 2014 24;8:1619-27. Epub 2014 Nov 24.

Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PPA.S70712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246993PMC
December 2014

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Eur J Haematol 2014 28;92(5):413-20. Epub 2014 Jan 28.

Hematology Research Unit Helsinki, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.12258
Publisher Site
http://dx.doi.org/10.1111/ejh.12258DOI Listing
December 2014

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.

Leuk Lymphoma 2014 Apr 25;55(4):934-7. Epub 2013 Jul 25.

Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital , Helsinki , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.812788DOI Listing
April 2014

[Current therapy of chronic myeloid leukemia].

Duodecim 2012 ;128(6):579-88

Hematologinen tutkimusyksikkö (HruH), HYKS: n hematologian klinikka.

View Article

Download full-text PDF

Source
May 2012